Marion Berdal

Marion Berdal

Auto-generated profile, based on publicly available information

Marion Berdal

Precirix NV/SA, Brussels, Belgium.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
MBMarion Berdal
Marion Berdal
SGSébastien GOUARD
Sébastien GOUARD
RERomain Eychenne
Romain Eychenne
SLSéverine Lambot
Séverine Lambot
MCMikael Croyal
Mikael Croyal
FGFrançois Guérard
François Guérard
Easy access to radioiodinated and 211At-labelled bio(macro)molecules is essential to develop new strategies in nuclear imaging and targeted radionuclide therapy of cancers. Yet, the labelling of complex molecules with heavy radiohalogens is often poorly effective due to the multiple steps and intermediate purifications needed. Herein, we investigate the potential of arylboron chemistry as an alternative approach for the late stage labelling of antibodies. The reactivity of a model precursor, 4-chlorobenzeneboronic acid (1) with nucleophilic iodine-125 and astatine-211 was at first investigated in aqueous conditions. In the presence of a copper(II) catalyst and 1,10-phenanthroline, quantitative radiochemical yields (RCYs) were achieved within 30 minutes at room temperature. The optimum conditions were then applied to a CD138 targeting monoclonal antibody (mAb) that has previously been validated for imaging and therapy in a preclinical model of multiple myeloma. RCYs remained high (>80% for 125I-labelling and >95% for 211At-labelling), and the whole procedure led to increased specific activities within less time in comparison with previously reported methods. Biodistribution study in mice indicated that targeting properties of the radiolabelled mAb were well preserved, leading to a high tumour uptake in a CD138 expressing tumour model. The possibility of divergent synthesis from a common modified carrier protein demonstrated herein opens facilitated perspectives in radiotheranostic applications with the radioiodine/211At pairs. Overall, the possibility to develop radiolabelling kits offered by this procedure should facilitate its translation to clinical applications.

29 December 2021 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
CMClémence Maingueneau
Clémence Maingueneau
MBMarion Berdal
Marion Berdal
RERomain Eychenne
Romain Eychenne
JGJoëlle Gaschet
Joëlle Gaschet
MCMichel Chérel
Michel Chérel
FGFrançois Guérard
François Guérard
Despite the growing interest in radioiodine and 211At‐labeled radiopharmaceuticals, the search for radiolabeling reactions has been somewhat neglected, resulting in a limited number of available radiosynthetic strategies. Herein we report a comparative study of nucleophilic 125I and 211At‐labeling of aryliodonium ylides. Whereas radioiodination efficiency was low, 211At‐labeling performed efficiently on a broad scope of precursors. The most activated aryliodonium ylides led rapidly to quantitative reactions at room temperature in acetonitrile. For deactivated precursors, heating up to 90 °C in glyme and addition of 2,2,6,6‐tetramethylpiperidine‐1‐oxyl (TEMPO) as radical scavenger appeared essential to avoid precursor degradation and to achieve high radiochemical yields and molar activity. The approach was applied successfully to the preparation of 4‐[211At]astatophenylalanine (4‐APA), an amino acid derivative increasingly studied as radiotherapeutic drug for cancers. This validated aryliodonium ylides as a valuable tool for nucleophilic 211At‐labeling and will complement the short but now growing list of available astatination reactions.

4 April 2026
Verified
Thesis
Closed access
MBMarion Berdal
Marion Berdal
L’astate-211 est un radionucléide prometteur pour la thérapie alpha vectorisée des cancers. Cependant, les méthodes actuelles de radiomarquage d’anticorps avec ce radiohalogène présentent de nombreuses limites telles que des rendements non-optimaux ou l’utilisation de précurseurs toxiques, ce qui complique son transfert en clinique. Afin de proposer des alternatives plus viables, l’exploration de nouvelles classes de précurseurs permettant le radiomarquage avec l’astate-211 et l’iode-125 sous forme nucléophile a été menée. Dans un premier temps, la synthèse de composés modèles pour chacune de ces classes et leur comparaison en termes d’efficacité a été réalisée afin d’identifier les plus adaptées pour le radiomarquage avec ces deux radionucléides. Dans une deuxième partie, la faisabilité d’un radiomarquage d’anticorps à l’astate-211 et à l’iode-125 en une seule étape, utilisant les acides arylboroniques, a été investigué. Dans un premier temps, l’étude de réactivité sur un composé modèle simple a été effectuée afin d’identifier des conditions efficaces en milieu aqueux et à basse température avant de transférer cette approche à un anticorps anti- CD138 d’intérêt pour le ciblage du myélome multiple. Le nouveau procédé ainsi développé surpasse les autres méthodes rapportées dans la littérature et a été validé par des études précliniques de biodistributions. Cette nouvelle méthode de radiomarquage devrait faciliter le passage de l’astate-211 en clinique et permettre le développement d’outils théranostiques basés sur la paire astate/iode.

18 June 2026 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
MBMarion Berdal
Marion Berdal
SNSurasa Nagachinta
Surasa Nagachinta
XLXimena Langsberg
Ximena Langsberg
VGVaiva Gaspariunaite
Vaiva Gaspariunaite
SMSam Massa
Sam Massa
LNLaurent Navarro
Laurent Navarro
Fibroblast activation protein is a well-established target for tumour imaging, and single-domain antibodies (sdAb) offer favourable pharmacokinetic properties for PET applications. However, the translation of sdAb-based radiotracers into robust and clinically applicable manufacturing processes remains limited. Previously, preclinical protocol for the production of [68Ga]Ga-DOTA-4AH29 has been reported. In this study, this process was adapted for clinical use. Both a manual, kit-based approach and automated synthesis on two different platforms were developed. Process robustness was assessed through a stress study evaluating key parameters, and compatibility with two 68Ga generator systems was investigated. Efficient radiolabelling was achieved at 50 °C for 10 min, with radiochemical conversion exceeding 90% and no need for purification. Both automated and manual processes showed consistent performance, with radiochemical purities of 99.5 ± 0.5% (n = 9) and 96.3 ± 1.5% (n = 8) as determined by iTLC and SE-HPLC respectively, with associated non-decay-corrected radiochemical yields of 78.3 ± 3.3% (n = 9) and 76.9 ± 2.1% (n = 8). The main source of activity loss was the radioactive decay of 68Ga.The process remained stable across a range of activities and buffer conditions. Comparable results were obtained with both 68Ga generator systems, with no observable impact on product quality. The final product was stable for at least 3 h at RT, with preserved binding capacity. A robust and reproducible manufacturing process for [68Ga]Ga-DOTA-4AH29 was established, supporting both automated and manual clinical production. This approach will facilitate broader access to sdAb-based PET imaging across clinical centres.